Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10306
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSeeman, Egoen
dc.contributor.authorCompston, Jen
dc.contributor.authorAdachi, Jen
dc.contributor.authorBrandi, M Len
dc.contributor.authorCooper, Cen
dc.contributor.authorDawson-Hughes, Ben
dc.contributor.authorJönsson, Ben
dc.contributor.authorPols, Hen
dc.contributor.authorCramer, J Aen
dc.date.accessioned2015-05-15T23:43:09Z-
dc.date.available2015-05-15T23:43:09Z-
dc.date.issued2007-01-24en
dc.identifier.citationOsteoporosis International : A Journal Established As Result of Cooperation Between the European Foundation For Osteoporosis and the National Osteoporosis Foundation of The Usa 2007; 18(6): 711-9en
dc.identifier.govdoc17245547en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10306en
dc.description.abstractAbout 50% of patients fail to comply or persist with anti-osteoporosis treatment regimens within 1 year. Poor compliance is associated with higher fracture rates. Causes of poor compliance are unknown. As it is not possible to predict poor compliance, close monitoring of compliance is needed. Despite evidence supporting the anti-fracture efficacy of several pharmacological agents, approximately 50% of patients do not follow their prescribed treatment regimen and/or discontinue treatment within 1 year. Poor compliance is associated with higher fracture rates and increased morbidity, mortality and cost. However, as poor compliance, even to placebo, is associated with adverse outcomes, the higher morbidity appears to be only partly the result of lack of treatment: as yet, undefined characteristics place poor compliers at higher risk of morbidity and mortality. Only a small proportion (e.g., 6%) of the variability in compliance is explained by putative causal factors such as older age, co-morbidity or greater number of medications. Regimens with longer dosing intervals, such as weekly dosing, improve compliance, persistence and outcomes, but only modestly. As it is not possible to predict poor compliance, close monitoring of compliance should be an obligatory duty in clinical care. How this is best achieved has yet to be established, but poor persistence occurs as early as 3 months of starting treatment, indicating the need for early monitoring.en
dc.language.isoenen
dc.subject.otherBone Density Conservation Agents.therapeutic useen
dc.subject.otherFemaleen
dc.subject.otherFractures, Bone.etiology.prevention & controlen
dc.subject.otherHumansen
dc.subject.otherOsteoporosis.complications.drug therapyen
dc.subject.otherPatient Complianceen
dc.subject.otherRisk Factorsen
dc.titleNon-compliance: the Achilles' heel of anti-fracture efficacy.en
dc.typeJournal Articleen
dc.identifier.journaltitleOsteoporosis Internationalen
dc.identifier.affiliationDepartment of Medicine and Endocrinology, Austin Health, University of Melbourne, Melbourne, Australiaen
dc.identifier.doi10.1007/s00198-006-0294-8en
dc.description.pages711-9en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/17245547en
dc.type.austinJournal Articleen
local.name.researcherSeeman, Ego
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextWith Fulltext-
item.grantfulltextopen-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptEndocrinology-
Appears in Collections:Journal articles
Files in This Item:
File SizeFormat 
17245547.pdf67.17 kBAdobe PDFView/Open
Show simple item record

Page view(s)

20
checked on Mar 28, 2024

Download(s)

80
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.